

# David Wirtshafter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3967974/publications.pdf>

Version: 2024-02-01

22  
papers

356  
citations

840776

11  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Behavioral and physiological characterization of PKC-dependent phosphorylation in the Grin2a <sup>+/+</sup> PKC mouse. <i>Brain Research</i> , 2016, 1646, 315-326.	2.2	3
2	Chemogenetic inhibition of cells in the paramedian midbrain tegmentum increases locomotor activity in rats. <i>Brain Research</i> , 2016, 1632, 98-106.	2.2	8
3	Dopamine is differentially involved in the locomotor hyperactivity produced by manipulations of opioid, GABA and glutamate receptors in the median raphe nucleus. <i>Behavioural Brain Research</i> , 2014, 261, 65-70.	2.2	12
4	Manipulation of GABA in the ventral pallidum, but not the nucleus accumbens, induces intense, preferential, fat consumption in rats. <i>Behavioural Brain Research</i> , 2014, 270, 316-325.	2.2	25
5	Lateral hypothalamic involvement in feeding elicited from the ventral pallidum. <i>European Journal of Neuroscience</i> , 2013, 37, 648-653.	2.6	23
6	Effects of muscimol in the nucleus accumbens shell on salt appetite and sucrose intake: A microstructural study with a comment on the sensitization of salt intake.. <i>Behavioral Neuroscience</i> , 2012, 126, 699-709.	1.2	7
7	Evidence that the nucleus accumbens shell, ventral pallidum, and lateral hypothalamus are components of a lateralized feeding circuit. <i>Behavioural Brain Research</i> , 2012, 226, 548-554.	2.2	48
8	Opposite effects on the ingestion of ethanol and sucrose solutions after injections of muscimol into the nucleus accumbens shell. <i>Behavioural Brain Research</i> , 2011, 216, 514-518.	2.2	27
9	Inactivation of the median raphe nucleus increases intake of sucrose solutions: A microstructural analysis.. <i>Behavioral Neuroscience</i> , 2011, 125, 529-540.	1.2	6
10	Evidence for motivational effects elicited by activation of GABA-A or dopamine receptors in the nucleus accumbens shell. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 96, 342-346.	2.9	32
11	Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 86, 505-510.	2.9	7
12	The selective m1 muscarinic antagonist MT-7 blocks pilocarpine-induced striatal Fos expression. <i>Brain Research</i> , 2006, 1085, 127-131.	2.2	8
13	The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. <i>European Journal of Pharmacology</i> , 2005, 528, 88-94.	3.5	17
14	Cholinergic involvement in the cortical and hippocampal Fos expression induced in the rat by placement in a novel environment. <i>Brain Research</i> , 2005, 1051, 57-65.	2.2	31
15	Role of dopamine D1 receptors in the striatal and cortical fos expression induced by the muscarinic agonist pilocarpine. <i>European Journal of Pharmacology</i> , 2004, 488, 85-90.	3.5	8
16	The distribution of m4 muscarinic acetylcholine receptors in the islands of Calleja and striatum of rats and cynomolgus monkeys. <i>Journal of Chemical Neuroanatomy</i> , 2004, 28, 107-116.	2.1	9
17	NPY mediates the feeding elicited by muscimol injections into the nucleus accumbens shell. <i>NeuroReport</i> , 2004, 15, 2673-2676.	1.2	22
18	Role of dopamine D2 receptors in the striatal immediate early gene response to amphetamine in reserpinized rats. <i>Brain Research Bulletin</i> , 2003, 62, 77-83.	3.0	5

#	ARTICLE	IF	CITATIONS
19	Effects of haloperidol and clozapine on Fos expression in the primate striatum. <i>NeuroReport</i> , 2003, 14, 2429-2432.	1.2	13
20	D1 dopamine receptors mediate neuroleptic-induced Fos expression in the islands of Calleja. , 1998, 28, 154-159.		10
21	Serotonin depletion and inhibition: Running the rat race without any brakes?. <i>Behavioral and Brain Sciences</i> , 1986, 9, 347-348.	0.7	0
22	Clonidine produces a conditioned place preference in rats. <i>Psychopharmacology</i> , 1985, 85, 383-385.	3.1	35